Purpose: Cancer treatment can be a complex and confusing process for both the patients and the care providers. With an ever-increasing array of treatment options, a push toward personalized medicine, and a complex payer system, coordination of cancer care is essential in streamlining the process. At Intermountain Healthcare, we have developed a hospital-based multidisciplinary cancer clinic that provides coordinated and comprehensive treatment planning in a single visit. Provider participation is open to employed, affiliated, and community physicians.
Methods: The first multidisciplinary clinic, which was for breast cancer, was held in 2005. Similar clinics for other tumor types have subsequently been instituted, including clinics for genitourinary/prostate, GI/liver/pancreas, sarcoma, and thoracic cancer. Each clinic is staffed by a surgeon, medical oncologist, radiation oncologist, and other specialists as needed. Clinic meetings are held immediately following a specialty tumor conference during which each patient is discussed. The patients then meet one-on-one with each specialist and leave the clinic with an individualized treatment plan. Patient and physician satisfaction surveys are regularly conducted. Financial metrics are calculated to track downstream revenue.
Results: Satisfaction with the clinic has been high, and 98% of patients rated their overall experience as "excellent." Physicians also give the clinic high marks, crediting it with improving communication, building patient confidence, and increasing efficiency.
Conclusion: The multidisciplinary clinic at Intermountain Healthcare has greatly improved the cancer care process for patients, physicians, and the community. If implemented appropriately, multidisciplinary clinics have the potential to enhance quality of care and increase downstream revenue.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2988677 | PMC |
http://dx.doi.org/10.1200/JOP.2010.000028 | DOI Listing |
Curr Oncol Rep
January 2025
Radiation Oncology Department, General Regional Hospital "F.Miulli", Acquaviva Delle Fonti, Bari, Italy.
Purpose Of Review: Male breast cancer (MBC) is a rare entity which often arises in elderly people. Aim of this review is to evaluate the principal issues related to MBC in elderly, because the therapeutic management of disease is not only related to the biological behavior of the tumor, but also to the comorbidities and frailty of older population. A scoping literature review was performed on Pubmed and Cochrane Database using the following keywords: therapeutic management/ male/ breast cancer/ elderly patients.
View Article and Find Full Text PDFBiotechnol Lett
January 2025
Extremophile and Productive Microorganisms Research Center, Kerman University of Medical Sciences, Kerman, Iran.
Selenium is an essential element with various industrial and medical applications, hence the current considerable attention towards the genesis and utilization of SeNPs. SeNPs and other nanoparticles could be achieved via physical and chemical methods, but these methods would not only require expensive equipment and specific reagents but are also not always environment friendly. Biogenesis of SeNPs could therefore be considered as a less troublesome alternative, which opens an excellent window to the selenium and nanoparticles' world.
View Article and Find Full Text PDFJ Cancer Surviv
January 2025
Leeds Institute of Medical Research at St James's, University of Leeds, Leeds, UK.
Purpose: Radiotherapy (RT) for oropharyngeal cancer (OPC) can lead to late toxicity. Fatigue is a known debilitating issue for many cancer survivors, yet prevalence and severity of long-term fatigue in patients treated for OPC is unknown.
Method: As part of a mixed-methods study, fatigue in OPC patients ≥ 2 years post RT + / - chemotherapy was evaluated.
J Cancer Res Clin Oncol
January 2025
German Cancer Research Center (DKFZ), Heidelberg, Germany.
Asia Pac J Clin Oncol
January 2025
LifeStrands Genomics Australia, Mount Waverley, Victoria, Australia.
Some patients with metastatic castration-resistant prostate cancer (mCRPC) possess germline or acquired defects in the DNA damage repair (DDR) genes BRCA1 and BRCA2. Tumors with BRCA mutations exhibit sensitivity to poly-ADP ribose polymerase inhibitors (PARPi) such as olaparib and rucaparib. As a result, molecular diagnostic testing to identify patients with BRCA mutations eligible for the PARPi therapy has become an integral component of managing patients with mCRPC.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!